Alpha Innotech Corp. (OTCBB:APNO) today announced that it has entered into a five year Strategic Supplier Alliance Agreement with GE Healthcare (NYSE:GE). This agreement is a continuation and expansion of the previous OEM Agreement signed between the two companies in April of 2005.
Under the terms of the agreement, Alpha Innotech will continue to develop, manufacture and supply a full line of proprietary imaging systems to GE Healthcare. The products will be sold exclusively worldwide under the GE brand in the life science research and drug discovery markets.
“Over the past three years we have built a very strong relationship with GE Healthcare and are pleased to extend our partnership in commercializing life sciences imaging systems,” stated Sia Ghazvini, Vice President for Marketing and Business Development at Alpha Innotech. “Combining GE Healthcare’s worldwide reach and expertise in biological applications with Alpha Innotech’s expertise in imaging technologies will provide researchers with completely integrated products for their research.”
“We are happy to extend our partnership with Alpha Innotech and to work closely with them providing leading edge scientific imaging systems and developing next generation products. Our partnership with Alpha Innotech expands our imaging portfolio and provides researchers with a broad choice of imaging modalities,” said Ron Alves, Purchase Family Leader, GE Healthcare. “Alpha Innotech continues to be our partner because their commitment to company values and product performance complements our own.”
About Alpha Innotech Corp.
Founded in 1992 and with over 10,000 systems sold worldwide, Alpha Innotech is a leading developer, manufacturer and marketer of digital imaging and analysis systems for the life science research and drug discovery markets. Our goal is to combine instruments, reagents and bioinformatics software to offer integrated modular technology platforms for functional genomics, proteomics and cell analysis markets. Our customers include pharmaceutical and biotechnology companies as well as universities, medical centers, government research institutes and agencies worldwide. More information on Alpha Innotech can be found at the Company’s website www.alphainnotech.com.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Its expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Its vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE:GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit its website at www.gehealthcare.com.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections. These forward-looking statements involve a number of risks and uncertainties that include, but are not limited to, the Company’s ability to obtain additional financing if needed, the timing of the introduction and success of new products, and the Company’s growth prospects, that could cause actual results to differ materially from those anticipated or planned by these forward-looking statements. Please also refer to the risk factors described in our filings with the Securities and Exchange Commission, including our recent Form 10-KSB and Form 10-Q filed with the Securities and Exchange Commission. We do not intend to update the forward-looking information contained in this news release except as required by law.
Comments